GTX-104
Phase 3Small molecule
GTX-104 is one of 26 small molecule programs targeting Oral. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Oral
#DrugCompanyPhaseTrials
1Vepesid
AAvyxa
Phase 2
Marinol
Jazz PharmaceuticalsPhase 1
GTX-104
GGrace Therapeutics Inc.
Phase 3
SHR-3167
JJiangsu HengRui Medicine Co., Ltd.
Phase 2
Pitressin
AAultman Health Foundation
Preclinical
Nubain
AAultman Health Foundation
Preclinical
DRSP/EE
Vertex PharmaceuticalsPhase 1
VX-407
Vertex PharmaceuticalsPhase 1
AB-101
AArtiva Biotherapeutics, Inc.
Phase 1
Nascobal
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GTX-104. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGrace Therapeutics Inc.